Korjuny
What Korjuny is used for
Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Korjuny
- Active substance
- catumaxomab
- Disease area
- Ascites
- Medicine group
- Antineoplastic agents
- ATC code
- L01FX03
- Marketing authorisation holder
- Atnahs Pharma Netherlands B.V.
- Authorised in the EU since
- 2025
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Korjuny used for?
Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.
What is the active substance in Korjuny?
Korjuny contains catumaxomab.
Who makes Korjuny?
The EU marketing authorisation holder is Atnahs Pharma Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU